Inhibition of α-, β-, γ-, and δ-carbonic anhydrases from bacteria and diatoms with N′-aryl-N-hydroxy-ureas

Emanuela Berrino, Murat Bozdag, Sonia Del Prete, Fatmah A. S. Alasmary, Linah S. Alqahtani, Zeid AlOTHMAN, Clemente Capasso and Claudiu T. Supuran

ABSTRACT

The inhibition of α-, β-, γ-, and δ-class carbonic anhydrases (CAs, EC 4.2.1.1) from bacteria (Vibrio cholerae and Porphyromonas gingivalis) and diatoms (Thalassiosira weissflogii) with a panel of N′-aryl-N-hydroxy-ureas is reported. The α-/β-CAs from V. cholerae (VchCAα and VchCAβ) were effectively inhibited by some of these derivatives, with KiS in the range of 97.5 nM – 7.26 μM and 52.5 nM – 1.81 μM, respectively, whereas the γ-class enzyme VchCAγ was less sensitive to inhibition (Kis of 4.75 – 8.87 μM). The β-CA from the pathogenic bacterium Porphyromonas gingivalis (PgiCAβ) was not inhibited by these compounds (Kis > 10 μM) whereas the corresponding γ-class enzyme (PgiCAγ) was effectively inhibited (Kis of 59.8 nM – 6.42 μM). The δ-CA from the diatom Thalassiosira weissflogii (TweCAδ) showed effective inhibition with these derivatives (Kis of 33.3 nM – 8.74 μM). As most of these N-hydroxy-ureas are also ineffective as inhibitors of the human (h) widespread isoforms hCA I and II (Kis > 10 μM), this class of derivatives may lead to the development of CA inhibitors selective for bacterial/diatom enzymes over their human counterparts and thus to anti-infectives or agents with environmental applications.

1. Introduction

N-Hydroxyurea has been reported by our group as a new chemotype of inhibitors of the metallo-enzyme carbonic anhydrase (CA, EC 4.2.1.1). This simple compound has been shown to bind in an unprecedented manner to the metal ion from this enzyme active site (more precisely the human (h) isoform hCA II), by means of X-ray crystallographic and kinetic studies. Although N-hydroxyurea is a weak, micromolar inhibitor, it was observed to coordinate bidentately to the Zn(II) ion from the hCA II active site, both through its NH and OH groups of the CONH2 fragment of the molecule (presumably deprotonated), which is rather unusual, as all the previously investigated inhibitors at that time were monodentate zinc ligands. This discovery led to the detailed investigation of organic hydroxyanilines (RCONH2) as CA inhibitors (CAIs), which are quite diverse from the main class, prototypical inhibitors of these enzymes, which are the sulfonamides and their isosteres, sulfamates, and sulfamides, all of them incorporating the SO2NH2 moiety as zinc-binding scaffold attached to the second nitrogen atom (compared to the simple lead molecule, N-hydroxyurea) and which proved to be effective inhibitors of the tumor-associated isoforms hCA IX/XII, without inhibiting considerably the off-target, house-keeping cytosolic isoforms hCA I and II, which are responsible for the many side effects seen with the sulfonamide type of CAIs.

KEYWORDS

Carbonic anhydrase; metalloenzymes; protozoa; activators; Plasmodium falciparum

CONTACT

Claudiu T. Supuran claudiu.supuran@unifi.it Dipartimento Neurofarba, Sezione di Scienze Farmaceutiche e Nutraceutiche, Università degli Studi di Firenze, Via U. Schiff 6, Sesto Fiorentino, Florence, 50019, Italy

© 2018 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

ARTICLE HISTORY

Received 4 May 2018
Revised 13 June 2018
Accepted 13 June 2018

1. Introduction

N-Hydroxyurea has been reported by our group as a new chemotype of inhibitors of the metallo-enzyme carbonic anhydrase (CA, EC 4.2.1.1). This simple compound has been shown to bind in an unprecedented manner to the metal ion from this enzyme active site (more precisely the human (h) isoform hCA II), by means of X-ray crystallographic and kinetic studies. Although N-hydroxyurea is a weak, micromolar inhibitor, it was observed to coordinate bidentately to the Zn(II) ion from the hCA II active site, both through its NH and OH groups of the CONH2 fragment of the molecule (presumably deprotonated), which is rather unusual, as all the previously investigated inhibitors at that time were monodentate zinc ligands. This discovery led to the detailed investigation of organic hydroxyanilines (RCONH2) as CA inhibitors (CAIs), which are quite diverse from the main class, prototypical inhibitors of these enzymes, which are the sulfonamides and their isosteres, sulfamates, and sulfamides, all of them incorporating the SO2NH2 moiety as zinc-binding scaffold attached to the second nitrogen atom (compared to the simple lead molecule, N-hydroxyurea) and which proved to be effective inhibitors of the tumor-associated isoforms hCA IX/XII, without inhibiting considerably the off-target, house-keeping cytosolic isoforms hCA I and II, which are responsible for the many side effects seen with the sulfonamide type of CAIs.

2. Materials and methods

2.1. Chemistry

Compounds 1–20 were prepared as reported earlier. Buffers and acetazolamide (AAZ) were commercially available, highest purity reagents from Sigma-Aldrich/Merck, Milan, Italy.
2.2. CA enzyme inhibition assay

An Sx.18Mv-R Applied Photophysics (Oxford, UK) stopped-flow instrument has been used to assay the catalytic activity of various CA isoforms for CO2 hydration reaction. Phenol red (at a concentration of 0.2 mM) was used as indicator, working at the absorbance maximum of 557 nm, with 10 mM HEPES (pH 7.5, for α- and δ-CAs) or tris (pH 8.3, for β- and γ-CAs) as buffers, 0.1 M sodium sulphate (for maintaining constant ionic strength), following the CA-catalyzed CO2 hydration reaction for a period of 10 s at 25°C. The CO2 concentrations ranged from 1.7 to 17 mM for the determination of the kinetic parameters and inhibition constants. For each inhibitor at least six traces of the initial 5–10% of the reaction have been used for determining the initial velocity. The uncatalyzed rates were determined in the same manner and subtracted from the total observed rates. Stock solutions of inhibitors (10 mM) were prepared in distilled-deionized water and dilutions up to 1 nM were done thereafter with the assay buffer. Enzyme and inhibitor solutions were pre-incubated together for 15 min (standard assay at room temperature) prior to assay, in order to allow for the formation of the enzyme-inhibitor complex. The inhibition constants were obtained by non-linear least-squares methods using PRISM 3 and the Cheng-Prusoff equation, as reported earlier. All CAs were recombinant proteins produced as reported earlier by our groups.

3. Results and discussion

Bacterial, fungal, protozoan, or other organisms CAs may represent new drug targets for the development of anti-infectives with an alternative mechanism of action to clinically used agents, but this type of research was rather neglected for a long time. Only in the last several years, mainly our group, cloned and investigated the inhibition of many parasite CAs from various organisms and belonging to a multitude of enzyme classes, providing the proof-of-concept experiments that parasite CA inhibitors may have a significant anti-infective effect, in vitro and in vivo, for many widespread pathogens such as those provoking malaria, Chagas disease, Leishmania, or Helicobacter pylori infection.

The rationale to investigate the new N'-aryl-N-hydroxyureas of compound type 1–20 as inhibitors of bacterial/diatom CAs, is based on the recent reported of Bozdag et al. that these compounds act as hCA IX/XII-selective inhibitors over hCA I and II (Table 1). In this article we included in the investigations the three CAs from the bacterial pathogen Vibrio cholerae (VchCAs/β/γ), the two CAs from the oral bacterial pathogen Porphyromonas gingivalis (PgiCAs/β/γ) as well as the uniquely well investigated δ-class CA, TweCAδ, from the diatom Thalassiosira weissflogii.

Inhibition data of the six CAs mentioned above with Compounds 1–20 and acetazolamide (AAZ) as standard, sulfonamide inhibitor, are shown in Table 2. The following structure-activity relationship (SAR) is observed from thee data of Table 2:

i. VchCAs was inhibited by some but not all Compounds 1–20 with Ks in the range of 97.5 nM − 7.26 μM (Table 2). The best inhibitors were Compounds 2 and 9 (Ks of 111.5 and 97.5 nM, respectively) and both of them have a Me-Ph moiety in their molecule (Compound 9 has also a second methyl group). It seems that these two substitution patterns of the aromatic ring are particularly effective for inhibiting this enzyme. The nitro-containing derivatives (Compounds 7 and 8), as well as the 2-Me derivative (Compound 3) were

| Cmp | hCA I | hCA II | hCA IX | hCA XII |
|-----|-------|--------|--------|---------|
| 1   | >10,000 | >10,000 | >10,000 | 27.4  |
| 2   | >10,000 | >10,000 | >10,000 | 253.2 |
| 3   | >10,000 | >10,000 | >10,000 | >10,000 |
| 4   | >10,000 | >10,000 | 8237.3 | 491.2 |
| 5   | >10,000 | >10,000 | >10,000 | 808.8 |
| 6   | >10,000 | >10,000 | >10,000 | >10,000 |
| 7   | >10,000 | >10,000 | 7781.7 | 43.6  |
| 8   | >10,000 | >10,000 | >10,000 | 529.2 |
| 9   | >10,000 | >10,000 | >10,000 | >10,000 |
| 10  | >10,000 | >10,000 | >10,000 | 768.0 |
| 11  | >10,000 | >10,000 | >10,000 | 858.2 |
| 12  | >10,000 | >10,000 | 253.5  | >10,000 |
| 13  | >10,000 | >10,000 | 679.1  | 27.9  |
| 14  | >10,000 | >10,000 | 78.9   | 7.2   |
| 15  | >10,000 | >10,000 | >10,000 | >10,000 |
| 16  | >10,000 | >10,000 | >10,000 | >10,000 |
| 17  | >10,000 | >10,000 | 268.9  | 51.3  |
| 18  | >10,000 | >10,000 | 130.0  | 42.1  |
| 19  | >10,000 | >10,000 | >10,000 | 377.6 |
| 20  | >10,000 | >10,000 | >10,000 | 746.6 |

*Mean from three different assays, by a stopped flow technique (errors were in the range of ±5–10% of the reported values).”
the next best VchCA\(\alpha\) inhibitors, with \(K_s < 1 \mu M\), whereas the remaining derivatives (Compounds 1–6) were weaker, micromolar inhibitors. Strangely enough, all Compounds 11–20 showed \(K_s > 10 \mu M\), which proves that small changes in the substitution pattern at the aromatic ring has dramatic consequences for the CA inhibitory activity.

ii. VchCA\(\beta\) showed a rather similar behavior, as Compounds 1–10 were effective inhibitors (\(K_s\) in the range of 52.5 nM - 1.81 \(\mu M\)), whereas Compounds 11–20 were not inhibitory (\(K_s > 10 \mu M\)). The best inhibitors were Compounds 5–9 (\(K_s\) in the range of 52.5 nM - 64.2 nM) and they incorporate nitro, chloro, and 2,5-dimethylphenyl moieties. The position of the R group on the phenyl moiety is crucial, since isomers such as Compounds 4 and 5/6 differ by an order of magnitude in their inhibitory action (Table 2). The 4-chloroderivative (Compound 4) is roughly 10 times a weaker VchCA\(\beta\) inhibitor compared to the 2- or 3-chlorosubstituted isomers (Compounds 5 and 6). Compounds 1–4 were medium potency inhibitors. It should be stressed that many of these \(N\)-hydroxyureas were more effective VchCA\(\beta\) inhibitors compared to acetazolamide (Table 1), such as for example Compounds 3 and 5–9.

iii. VchCA\(\gamma\) was generally poorly inhibited by most of the investigated \(N\)-hydroxyureas, except for Compounds 8, 9, 13, 14, 18, and 19, which were weak, micromolar inhibitors, \(K_s\) of 4.75 – 8.87 \(\mu M\). The remaining 14 derivatives in the series were not inhibitory at all up to 10 \(\mu M\) concentration of inhibitor in the assay system (Table 1). It is in fact know that the active site of \(\gamma\)-CAs is rather shallow compared to the deep ones of the \(\alpha\)- and \(\beta\)-class enzymes\(^3\).

iv. PgiCA\(\beta\) was not significantly inhibited by any of the \(N\)-hydroxyureas Compounds 1–20 investigated here, which is rather difficult to explain considering the fact that the X-ray crystal structure of this enzyme is unknown. AAZ is on the other hand a medium potency inhibitor of this enzyme, with a \(K_s\) of 214 nM.

v. The \(\gamma\)-CA from the same pathogenic bacterium, PgiCA\(\gamma\), was on the other hand sensitive to inhibition by many of the investigated \(N\)-hydroxyureas Compounds 1–20, which showed \(K_s\) ranging between 59.8 nM and 6.42 \(\mu M\) (Table 1). The best inhibitors were Compounds 8, 9, and 14, with \(K_s\) ranging between 59.8 and 84.4 nM. Again they contain nitrophenyl (Compounds 8 and 9) and methylthiol-phenyl (Compound 14) moieties in their molecule, which seem to be the best ones inducing an effective inhibitory activity against this enzyme. These three compounds were also much more effective than acetazolamide as PgiCA\(\gamma\) inhibitors.

vi. TwCA\(\lambda\) was poorly inhibited by Compounds 1–11, whereas Compounds 12–20 showed a more effective inhibitory activity, with \(K_s\) of 33.3 nM – 8.74 \(\mu M\) (Table 1). The best inhibitors were Compounds 12–14, with \(K_s\) of 33.3 – 57.8 nM and they incorporate various R moieties on the aryl fragment (3-methylthio, 2-ethoxy, and 2,5-dimethylphenyl). As for the other enzymes investigated here, the nature of the R moiety and substitution pattern on the aryl fragment are the main factors influencing the biological activity.

vii. The inhibition profile of these six CAs is very different between each other and also considering the human isoforms investigated earlier (hCA I, II, IX and XII)\(^14\), making this class of CAs of particular interest for developing class-selective inhibitors.

4. Conclusions

A series of 20 \(N\)-aryl-\(N\)-hydroxyureas possessing a variety of substitution patterns on the aryl fragment of the molecule, was investigated for the inhibition of six CAs belonging to four genetic families, from pathogenic bacteria and nonpathogenic diatoms. The \(\alpha\)/\(\beta\)-CAs from \textit{V. cholerae} (VchCA\(\alpha\) and VchCA\(\beta\)) were effectively inhibited by some of these derivatives, with \(K_s\) in the range of 97.5 nM – 7.26 \(\mu M\) and 52.5 nM – 1.81 \(\mu M\), respectively, whereas the \(\gamma\)-class enzyme VchCA\(\gamma\) was less sensitive to inhibition (\(K_s\) of 4.75 – 8.87 \(\mu M\)). The \(\beta\)-CA from the pathogenic bacterium \textit{Porphyromonas gingivalis} (PgiCA\(\beta\)) was not inhibited by these compounds (\(K_s > 10 \mu M\)) whereas the corresponding \(\gamma\)-class enzyme (PgiCA\(\gamma\)) was effectively inhibited (\(K_s\) of 59.8 nM – 6.42 \(\mu M\)). The \(\delta\)-CA from the diatom \textit{Thalassiosira weissflogii} (TweCA\(\delta\)) showed effective inhibition with these derivatives (\(K_s\) of 33.3 nM – 8.74 \(\mu M\)). As most of these \(N\)-hydroxyureas are also ineffective as inhibitors of the human (h) widespread isoforms hCA I and II (\(K_s > 10 \mu M\)), this class of derivatives may lead to the development of CA inhibitors selective for bacterial/diatom enzymes over their human counterparts and thus to anti-infectives or agents with environmental applications.

Disclosure statement

No potential conflict of interest was reported by the authors.

Funding

This research was financed in part by a Distinguished Scientists Fellowship Programme (DSFP) or King Saud University, Riyadh, Saudi Arabia.

ORCID

Claudiu T. Supuran \(\text{http://orcid.org/0000-0003-4262-0323}\)

References

1. a) Scozzaevaa A, Supuran CT. Hydroxyurea is a carbonic anhydrase inhibitor. Bioorg Med Chem 2003;11:2241–6. b) Temperini C, Innocenti A, Scozzaevaa A, Supuran CT. \(N\)-hydroxyurea – a versatile zinc binding function in the design of metalloenzyme inhibitors. Bioorg Med Chem Lett 2006:16:4316–20.

2. a) Supuran CT. Carbonic anhydrases: from biomedical applications of the inhibitors and activators to biotechnological use for \(\text{CO}_2\) capture. J Enzyme Inhib Med Chem 2013;28:229–30. b) Supuran CT. How many carbonic anhydrase inhibition mechanisms exist? J Enzyme Inhib Med Chem 2016;31:345–60. c) Alterio V, Fiore AD, D’Ambrosio K, et al. Multiple binding modes of inhibitors to carbonic anhydrases: how to design specific drugs targeting 15 different isoforms? Chem Rev 2012;112:4421–68. d) Abbatte F, Winum JY, Potter BV, et al. Carbonic anhydrase inhibitors: X-ray crystallographic structure of the adduct of human isozyme II with EMATE, a dual inhibitor of carbonic anhydrases and steroid sulfatase. Bioorg Med Chem Lett 2004;14:231–4. e) Capasso C, Supuran CT. An overview of the alpha-, beta- and gamma-carbonic anhydrases from Bacteria: can bacterial
carbonic anhydrases shed new light on evolution of bacteria? J Enzyme Inhib Med Chem 2015;30:325–32.

3. a) Supuran CT. Advances in structure-based drug discovery of carbonic anhydrase inhibitors. Expert Opin Drug Discov. 2017;12:61–88. b) Supuran CT. Structure and function of carbonic anhydrases. Biochem J 2016;473:2023–32. c) Supuran CT. Carbonic anhydrases: novel therapeutic applications for inhibitors and activators. Nat Rev Drug Discov. 2008;7:168–81. d) Neri D, Supuran CT. Interfering with pH regulation in tumours as a therapeutic strategy. Nat Rev Drug Discov 2011;10:767–77. e) Supuran CT, Vullo D, Manole G, et al. Designing of novel carbonic anhydrase inhibitors and activators. Curr Med Chem Cardiovasc Hematol Agents 2004;2:49–68.

4. a) D’Ambrosio K, Supuran CT, De Simone G. Are carbonic anhydrases suitable targets to fight protozoan parasitic diseases? Curr Med Chem 2018; doi: 10.2174/09296732566180326160121 (in press); b) Vermelho AB, Capaci GR, Rodrigues IA, et al. Carbonic anhydrases from Trypanosoma and Leishmania as antiprotozoan drug targets. Bioorg Med Chem 2017;25:1543–55. c) Supuran CT. Inhibition of carbonic anhydrase from Trypanosoma cruzi for the management of Chagas disease: an underexplored therapeutic opportunity. Future Med Chem 2016;8:311–24. d) Syrjänen L, Vermelho AB, Rodrigues Idé A, et al. Cloning, characterization, and inhibition studies of a β-carbonic anhydrase from Leishmania donovani chagasi, the protozoan parasite responsible for leishmaniasis. J Med Chem 2013;56:7372–81.

5. a) Capasso C, Supuran CT. Bacterial, fungal and protozoan carbonic anhydrases as drug targets. Expert Opin Ther Targets 2015;19:1689–704. b) Vermelho AB, da Silva Cardoso V, Ricci Junior E, et al. Nanoemulsions of sulfonamide carbonic anhydrase inhibitors strongly inhibit the growth of Trypanosoma cruzi. J Enzyme Inhib Med Chem 2018;33:139–46. c) de Menezes Dda R, Calvet CM, Rodrigues GC, et al. Hydroxamic acid derivatives: a promising scaffold for rational compound optimization in Chagas disease. J Enzyme Inhib Med Chem 2016;31:964–73. d) Nocentini A, Cadoni R, Dumy P, et al. Carbonic anhydrases from Trypanosoma cruzi and Leishmania donovani chagasi are inhibited by benzoaxaboroles. J Enzyme Inhib Med Chem 2018;33:286–9. e) Del Prete S, D, Luca V, De Simone G, Supuran CT, et al. Cloning, expression and purification of the complete domain of the β-carbonic anhydrase from Plasmodium falciparum. J Enzyme Inhib Med Chem 2016;31:54–9.

6. a) Supuran CT, Capasso C. The β-class carbonic anhydrases as drug targets for antimalarial agents. Expert Opin Ther Targets 2015;19:551–63. b) Vullo D, Del Prete S, Fisher GM, et al. Sulfonamide inhibition studies of the β-class carbonic anhydrase from the malaria pathogen Plasmodium falciparum. Bioorg Med Chem 2015;23:526–31. c) De Simone G, Di Fiore A, Capasso C, Supuran CT. The zinc coordination pattern in the β-carbonic anhydrase from Plasmodium falciparum is different from all other carbonic anhydrase genetic families. Bioorg Med Chem Lett 2015;25:1385–9.

7. a) Supuran CT. Carbon- versus sulphur-based zinc binding groups for carbonic anhydrase inhibitors? J Enzyme Inhib Med Chem 2018;33:485–95. b) Di Fiore A, Maresca A, Supuran CT, De Simone G. Hydroxamate represents a versatile zinc binding group for the development of new carbonic anhydrase inhibitors. Chem Commun (Camb) 2012;48:8838–40. c) Marques SM, Nuti E, Rossello A, et al. Dual inhibitors of matrix metalloproteinases and carbonic anhydrases: iminodiacetyl-based hydroxamate-benzensulfonylamide conjugates. J Med Chem 2008;51:7968–79.

8. a) Carta F, Supuran CT. Diuretics with carbonic anhydrase inhibitory action: a patent and literature review (2005–2013). Expert Opin Ther Pat 2013;23:681–91.

9. a) Masini E, Carta F, Scozzafava A, Supuran CT. Antiglaucoma carbonic anhydrase inhibitors: a patent review. Expert Opin Ther Pat 2013;23:705–16.

10. a) Scozzafava A, Supuran CT, Carta F. Antibesity carbonic anhydrase inhibitors: a literature and patent review. Expert Opin Ther Pat 2013;23:725–35. b) Supuran CT. Carbonic anhydrases and metabolism. Metabolites 2018;8:E25.

11. a) Monti SM, Supuran CT, De Simone G. Anticancer carbonic anhydrase inhibitors: a patent review (2008–2013). Expert Opin Ther Pat 2013;23:737–49. b) Supuran CT. Carbonic anhydrase inhibition and the management of hypoxic tumors. Metabolites 2017;7:E48. c) Ward C, Langdon SP, Mullen P, et al. New strategies for targeting the hypoxic tumour microenvironment in breast cancer. Cancer Treat Rev 2013;39:171–9. d) Garaj V, Puccetti L, Fasolis G, et al. Carbonic anhydrase inhibitors: novel sulfonamides incorporating 1,3,5-triazine moieties as inhibitors of the cytosolic and tumour-associated carbonic anhydrase isozymes I, II and IX. Bioorg Med Chem Lett 2005;15:3102–8.

12. a) Supuran CT. Carbonic anhydrase inhibition and the management of neuropathic pain. Expert Rev Neurother 2016;16:961–8. b) Di Cesare Mannelli L, Micheli L, Carta F, et al. Carbonic anhydrase inhibition for the management of cerebral ischemia: in vivo evaluation of sulfonamide and coumarin inhibitors. J Enzyme Inhib Med Chem 2016;31:894–9.

13. a) Margheri F, Ceruso M, Carta F, et al. Overexpression of the transmembrane carbonic anhydrase isoforms IX and XII in the inflamed synovium. J Enzyme Inhib Med Chem 2016;31(sup 4):60–3. b) Bua S, Di Cesare Mannelli L, Vullo D, et al. Design and synthesis of novel nonsteroidal anti-inflammatory drugs and carbonic anhydrase inhibitors hybrids (NSAIDs-CAIs) for the treatment of rheumatoid arthritis. J Med Chem 2017;60:1159–70.

14. Bozdag M, Carta F, Angeli A, et al. Synthesis of N′-phenyl-N′-hydroxyureas and investigation of their inhibitory activities on human carbonic anhydrases. Bioorg Chem 2018;78:1–6.

15. Khalifah RG. The carbon dioxide hydration activity of carbonic anhydrase I. Stop-flow kinetic studies on the native human isoenzymes B and C. J Biol Chem 1971;246:2561–73.

16. a) De Vita D, Angeli A, Pandolfi F, et al. Inhibition of the α-carbonic anhydrase from Vibrio cholerae with amides and sulfonamides incorporating imidazole moieties. J Enzyme Inhib Med Chem 2017;32:798–804. b) Del Prete S, Vullo D, De Luca V, et al. Sulfonamide inhibition studies of the β-carbonic anhydrase from the pathogenic bacterium Vibrio cholerae. Bioorg Med Chem 2016;11:15–20. c) Del Prete S, Isik S, Vullo D, et al. DNA cloning, characterization, and inhibition studies of an α-carbonic anhydrase from the pathogenic bacterium Vibrio cholerae. J Med Chem 2012;55:10742–8.
17. a) Del Prete S, Vullo D, De Luca V, et al. Anion inhibition profiles of \( \alpha \), \( \beta \) and \( \gamma \)-carbonic anhydrases from the pathogenic bacterium *Vibrio cholerae*. Bioorg Med Chem 2016;24:3413–7. b) Angeli A, Del Prete S, Osman SM, et al. Activation studies of the \( \alpha \) - and \( \beta \)-carbonic anhydrases from the pathogenic bacterium *Vibrio cholerae* with amines and amino acids. J Enzyme Inhib Med Chem 2018;33:227–33.

18. a) Alafeefy AM, Ceruso M, Al-Tamimi AM, et al. Inhibition studies of quinazoline-sulfonamide derivatives against the \( \gamma \)-CA (PgiCA) from the pathogenic bacterium, *Porphyromonas gingivalis*. J Enzyme Inhib Med Chem 2015;30:592–6. b) Del Prete S, Vullo D, D, Luca V, et al. Biochemical characterization of recombinant \( \beta \)-carbonic anhydrase (PgiCAβ) identified in the genome of the oral pathogenic bacterium *Porphyromonas gingivalis*. J Enzyme Inhib Med Chem 2015;30:366–70. c) Del Prete S, De Luca V, Vullo D, et al. Biochemical characterization of the \( \gamma \)-carbonic anhydrase from the oral pathogen *Porphyromonas gingivalis*, PgiCA. J Enzyme Inhib Med Chem 2014;29:532–7.

19. a) Del Prete S, Vullo D, De Luca V, et al. Biochemical characterization of the \( \delta \)-carbonic anhydrase from the marine diatom *Thalassiosira weissflogii*, TweCA. J Enzyme Inhib Med Chem 2014;29:906–11. b) Bua S, Bozdag M, Del Prete S, et al. Mono- and di-thiocarbamate inhibition studies of the \( \delta \)-carbonic anhydrase TweCA\( \delta \) from the marine diatom *Thalassiosira weissflogii*. J Enzyme Inhib Med Chem 2018;33:707–13.

20. a) Diaz JR, Fernández Baldo M, Echeverría G, et al. A substituted sulfonamide and its Co (II), Cu (II), and Zn (II) complexes as potential antifungal agents. J Enzyme Inhib Med Chem 2016;31:51–62. b) Menchise V, De Simone G, Alterio V, et al. Carbonic anhydrase inhibitors: stacking with Phe131 determines active site binding region of inhibitors as exemplified by the X-ray crystal structure of a membrane-impermeant antitumor sulfonamide complexed with isozyme II. J Med Chem 2005;48:5721–7. c) Supuran CT, Mincione F, Scozzafava A, et al. Metal complexes of heterocyclic sulfonamides: a new class of strong topical intraocular pressure-lowering agents in rabbits. Eur J Med Chem 1998;33:247–54. d) Garaj V, Puccetti L, Pacchiano F, Aggarwal M, Avvaru BS, et al. Selective hydrophobic pocket binding observed within the carbonic anhydrase II active site accommodate different 4-substituted-ureido-benzenesulfonamides and correlate to inhibitor potency. Chem Commun (Camb) 2010;46:8371–3.

22. a) Supuran CT, Nicolae A, Popescu A. Carbonic anhydrase inhibitors. Part 35. Synthesis of Schiff bases derived from sulfanilamide and aromatic aldehydes: the first inhibitors with equally high affinity towards cytosolic and membrane-bound isozymes. Eur J Med Chem 1996;31:431–8. b) Paccianco F, Aggarwal M, Avvaru BS, et al. Selective hydrophobic pocket binding observed within the carbonic anhydrase II active site accommodate different 4-substituted-ureido-benzenesulfonamides and correlate to inhibitor potency. Chem Commun (Camb) 2010;46:8371–3. c) Ozensoy Guler O, Capasso C, Supuran CT. A magnificent enzyme superfamily: carbonic anhydrases, their purification and characterization. J Enzyme Inhib Med Chem 2016;31:689–94. d) De Simone G, Langella E, Esposito D, et al. Insights into the binding mode of sulphanates and sulphamides to hCA II: crystallographic studies and binding free energy calculations. J Enzyme Inhib Med Chem 2017;32:1002–11. e) Winum JY, Temperini C, El Cheikh K, et al. Carbonic anhydrase inhibitors: clash with Ala65 as a means for designing inhibitors with low affinity for the ubiquitous isozyme II, exemplified by the crystal structure of the topiramate sulfamide analogue. J Med Chem 2006;49:7024–31.

23. a) Modak JK, Liu YC, Supuran CT, Roujeinikova A. Structure-activity Relationship for sulfonamide inhibition of *Helicobacter pylori* \( \alpha \)-carbonic anhydrase. J Med Chem 2016;59:11098–109. b) Buzás GM, Supuran CT. The history and rationale of using carbonic anhydrase inhibitors in the treatment of peptic ulcers. In memoriam Ioan Puşcaş (1932–2015). J Enzyme Inhib Med Chem 2016;31:527–33. c) Supuran CT. Bacterial carbonic anhydrases as drug targets: toward novel antibiotics? Front Pharmacol 2011;2:34. d) Nishimori I, Onishi S, Takeuchi H, Supuran CT. The alpha and beta classes carbonic anhydrases from *Helicobacter pylori* as novel drug targets. Curr Pharm Des 2008;14:622–30. e) Chohan ZH, Supuran CT, Scozzafava A. Metal binding and antibacterial activity of ciprofloxacin complexes. J Enzyme Inhib Med Chem 2005;20:303–7. Supuran CT, Capasso C. Carbonic anhydrase from *Porphyromonas gingivalis* as a drug target. Pathogens 2017;6:30.